Rapamycin and Dalotuzumab in combination inhibit parental and endocrine resistant breast cancer cells.

被引：0
|
作者：
Beckwith, H. [1 ]
Fettig-Anderson, L. [1 ]
Yueh, N. [1 ]
Douglas, Y. [1 ]
机构：
[1] Univ Minnesota, Minneapolis, MN USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P4-07-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-07-03
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro
    Limer, Jane L.
    Parkes, Alicia T.
    Speirs, Valerie
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (03) : 515 - 521
  • [22] Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
    Ladd, Brendon
    Mazzola, Anne Marie
    Bihani, Teeru
    Lai, Zhongwu
    Bradford, James
    Collins, Michael
    Barry, Evan
    Goeppert, Anne U.
    Weir, Hazel M.
    Hearne, Kelly
    Renshaw, Jonathan G.
    Mohseni, Morvarid
    Hurt, Elaine
    Jalla, Sanjoo
    Bao, Haifeng
    Hollingsworth, Robert
    Reimer, Corinne
    Zinda, Michael
    Fawell, Stephen
    D'Cruz, Celina M.
    ONCOTARGET, 2016, 7 (34) : 54120 - 54136
  • [23] Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer
    Shigehira Saji
    Reiko Kimura-Tsuchiya
    International Journal of Clinical Oncology, 2015, 20 : 268 - 272
  • [24] Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer
    Saji, Shigehira
    Kimura-Tsuchiya, Reiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (02) : 268 - 272
  • [25] Separate and Combined Actions of Tamoxifen and Metformin in Hormone Resistant Breast Cancer Cells.
    Berstein, L. M.
    Yue, W.
    Wang, J. P.
    Santen, R. J.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [26] Determinants of rapamycin sensitivity in breast cancer cells
    Noh, WC
    Mondesire, WH
    Peng, JY
    Jian, WG
    Zhang, HX
    Dong, JJ
    Mills, GB
    Hung, MC
    Meric-Bernstam, F
    CLINICAL CANCER RESEARCH, 2004, 10 (03) : 1013 - 1023
  • [27] Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer
    Chollet, Philippe
    Abrial, Catherine
    Tacca, Olivier
    Mouret-Reynier, Marie-Ange
    Leheurteur, Marianne
    Durando, Xavier
    Cure, Herve
    CLINICAL BREAST CANCER, 2006, 7 (04) : 336 - 338
  • [28] CD133 expression is affected by rapamycin in cancer cells.
    Matsumoto, Kazuko
    Arao, Tokuzo
    Tanaka, Kaoru
    Kaneda, Hiroyasu
    Kudo, Kanae
    Maegawa, Mari
    Tamura, Daisuke
    Aomatsu, Keiichi
    Fujita, Yoshihiko
    Yamada, Yasuhide
    Nishio, Kazuto
    CANCER RESEARCH, 2009, 69
  • [29] Antitumor activity of rapamycin in combination with ectopic expression of Beclin 1 in multidrug-resistant cancer cells
    Lee, Michael
    Ahn, Jun-Ho
    Eum, Ki-Hwan
    Kim, Yun-Ki
    FASEB JOURNAL, 2011, 25
  • [30] MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells
    Petri, Belinda J.
    Piell, Kellianne M.
    Wilt, Ali E.
    Howser, Alexa D.
    Winkler, Laura
    Whitworth, Mattie R.
    Valdes, Bailey L.
    Lehman, Norman L.
    Clem, Brian F.
    Klinge, Carolyn M.
    ENDOCRINE-RELATED CANCER, 2023, 30 (11)
12345